Durand: Psoriatic arthritis obviously is a bit more of a challenging autoimmune disease to treat. The GRAPPA recommendations are very important because there are 6 different domains, which is why ...
Please provide your email address to receive an email when new articles are posted on . Methotrexate increases the probability of remission with adalimumab or infliximab by 50% in patients with ...
"We believe that prescribing this combination in routine practice is viable when combined with shared decision-making and strict monitoring of side effects," write Michelle L. M. Mulder, MD, of the ...
SaveHealth reports on psoriatic arthritis medications, detailing options like DMARDs, biologics, and NSAIDs, including their ...
Please provide your email address to receive an email when new articles are posted on . To determine the efficacy of monotherapy with either methotrexate or etanercept (Enbrel, Amgen), as well as ...
Psoriatic arthritis (PsA) is a multifactorial condition that leads to chronic inflammation of the joints and entheses in around 10–30% of patients with psoriasis. Therapy for PsA is generally based ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Between May 2019 and March 2020, patients receiving MTX and/or ...
To examine the prevalence of side effects with methotrexate (MTX) and tumor necrosis factor inhibitors (TNFi) among patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA). This ...
SAN DIEGO, CA—A post-hoc analysis of two trials found patients with active psoriatic arthritis treated with etanercept with or without methotrexate combination therapy had similar clinical and ...
Women report losing access to crucial arthritis medication, methotrexate, due to state abortion bans
Denise Johnston stood in line at the pharmacy to pick up her monthly prescription of methotrexate, which she takes to relieve pain from her psoriatic arthritis. A month earlier, Johnston, 49, picked ...
Treatment with bimekizumab showed consistent efficacy through 52 weeks in patients with psoriatic arthritis in a post hoc analysis of the BE OPTIMAL, BE COMPLETE, and BE VITAL trials. The new analysis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback